- Home
- Publications
- Publication Search
- Publication Details
Title
Tirzepatide and potential use for metabolically healthy obesity
Authors
Keywords
-
Journal
European Journal of Internal Medicine
Volume 113, Issue -, Pages 1-5
Publisher
Elsevier BV
Online
2023-05-12
DOI
10.1016/j.ejim.2023.05.012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metabolically healthy obesity: Misleading phrase or healthy phenotype?
- (2023) Cem Tanriover et al. European Journal of Internal Medicine
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
- (2022) Dominik Dahl et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Advances in Phenotyping Obesity and in Its Dietary and Pharmacological Treatment: A Narrative Review
- (2022) Roberta Pujia et al. Frontiers in Nutrition
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
- (2022) Naveed Sattar et al. NATURE MEDICINE
- The actual burden of obesity—accounting for multimorbidity
- (2022) Avishai M Tsur et al. Lancet Diabetes & Endocrinology
- The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
- (2022) Han Na Jung et al. Journal of Obesity & Metabolic Syndrome
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pathogenesis, Murine Models, and Clinical Implications of Metabolically Healthy Obesity
- (2022) Yun Kyung Cho et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
- (2022) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Metabolomic Signature Between Metabolically Healthy Overweight/Obese and Metabolically Unhealthy Overweight/Obese: A Systematic Review
- (2021) Dihe Cheng et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- The evolving story of incretins ( GIP and GLP ‐1) in metabolic and cardiovascular disease: A pathophysiological update
- (2021) Michael A. Nauck et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Breaking New Ground with Incretin Therapy in Diabetes
- (2021) Katherine R. Tuttle NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
- (2021) Valentina Pirro et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- (2021) Stefano Del Prato et al. LANCET
- Metabolically Healthy Obesity—Heterogeneity in Definitions and Unconventional Factors
- (2020) Inês Brandão et al. Metabolites
- Metabolically Healthy Obesity: Criteria, Epidemiology, Controversies, and Consequences
- (2020) Agathocles Tsatsoulis et al. Current Obesity Reports
- How May GIP Enhance the Therapeutic Efficacy of GLP-1?
- (2020) Ricardo J. Samms et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Causes, consequences, and treatment of metabolically unhealthy fat distribution
- (2020) Norbert Stefan Lancet Diabetes & Endocrinology
- Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
- (2020) Maria Lucey et al. Molecular Metabolism
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
- (2020) Francis S. Willard et al. JCI Insight
- The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
- (2020) Jonathan M. Wilson et al. DIABETES OBESITY & METABOLISM
- Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
- (2020) Radica Z. Alicic et al. Nature Reviews Nephrology
- Metabolically healthy obese phenotype and risk of cardiovascular disease: Results from the China Health and Retirement Longitudinal Study
- (2019) Haibin Li et al. ARCHIVES OF GERONTOLOGY AND GERIATRICS
- Metabolically healthy obesity: what's in a name?
- (2019) Faidon Magkos AMERICAN JOURNAL OF CLINICAL NUTRITION
- Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data
- (2019) Morgan E. Grams et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Cellular mechanisms governing glucose-dependent insulinotropic polypeptide secretion
- (2019) Frank Reimann et al. PEPTIDES
- Incretin hormones: Their role in health and disease
- (2018) Michael A. Nauck et al. DIABETES OBESITY & METABOLISM
- Targeting GLP-1 receptor trafficking to improve agonist efficacy
- (2018) Ben Jones et al. Nature Communications
- Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses' Health Study): 30 year follow-up from a prospective cohort study
- (2018) Nathalie Eckel et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Metabolically Healthy Obesity and Ischemic Heart Disease: A 10-Year Follow-Up of the Inter99 Study
- (2017) Louise Hansen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women
- (2017) Rishi Caleyachetty et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults
- (2017) Leandra Abarca-Gómez et al. LANCET
- The long-term prognosis of cardiovascular disease and all-cause mortality for metabolically healthy obesity: a systematic review and meta-analysis
- (2016) Ruizhi Zheng et al. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH
- Risk of the Development of Diabetes and Cardiovascular Disease in Metabolically Healthy Obese People
- (2016) Nan Hee Kim et al. MEDICINE
- Visceral abdominal fat accumulation predicts the conversion of metabolically healthy obese subjects to an unhealthy phenotype
- (2015) Y-C Hwang et al. INTERNATIONAL JOURNAL OF OBESITY
- The Natural Course of Healthy Obesity Over 20 Years
- (2015) Joshua A. Bell et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used
- (2014) J. P. Rey-López et al. Obesity Reviews
- The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies
- (2014) Jana V van Vliet-Ostaptchouk et al. BMC Endocrine Disorders
- Determinants of the transition from a cardiometabolic normal to abnormal overweight/obese phenotype in a Spanish population
- (2013) Helmut Schröder et al. EUROPEAN JOURNAL OF NUTRITION
- Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories
- (2013) Katherine M. Flegal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults
- (2013) Ian J. Neeland et al. Obesity
- Pathophysiology of Human Visceral Obesity: An Update
- (2013) André Tchernof et al. PHYSIOLOGICAL REVIEWS
- Dysfunctional Adiposity and the Risk of Prediabetes and Type 2 Diabetes in Obese Adults
- (2012) Ian J. Neeland et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Identification and Characterization of Metabolically Benign Obesity in Humans
- (2008) Norbert Stefan ARCHIVES OF INTERNAL MEDICINE
- Patterns of Abdominal Fat Distribution: The Framingham Heart Study
- (2008) K. M. Pou et al. DIABETES CARE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now